Data for Lipodomics and Gestational bisphenol A (BPA) exposure (Study ST000686)

(Analysis AN001058)

Values for each metabolite have been scaled by dividing by the mean across all factors

Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study

MetaboliteF1F2F3F4
CerP 32:1; [M-H]-@5.21 1.3071 0.7825 1.0036 0.9523
CerP 34:1; [M-H]-@5.95 0.9301 0.8660 0.9887 1.1110
CerP 34:2; [M-H]-@5.45 1.0755 1.0243 1.0279 0.9278
CerP 35:1; [M-H]-@6.29 1.0023 1.0203 0.8437 1.1137
CerP 41:1; [M-H]-@8.23 0.9990 0.9257 0.9817 1.0523
CL 72:3; [M-2H](2-)@6.91 0.9705 0.9495 0.9366 1.0908
CL 76:5; [M-2H](2-)@7.09 1.2801 0.8712 0.9205 0.9879
FFA(16:0) 1.0479 0.8974 1.0746 0.9677
FFA(18:0) 1.0483 0.9198 1.0426 0.9819
FFA(18:1) 1.0713 0.8396 1.1044 0.9610
FFA(18:2) 1.0701 0.7957 1.1412 0.9541
FFA(20:0) 1.0473 0.9466 1.0161 0.9902
FFA(20:1) 1.0393 0.8319 1.1524 0.9425
FFA(20:2) 1.0502 0.7850 1.1995 0.9228
FFA(20:4) Arachidonic acid 1.1441 0.8694 1.0166 0.9800
FFA(22:0) 1.0333 0.8991 1.0062 1.0288
FFA(22:1) 0.8989 0.8335 1.0688 1.0788
FFA(22:2) 1.1363 0.7995 1.2096 0.8644
FFA(22:3) 0.9720 0.5740 1.2343 1.0395
FFA(24:0) 1.0430 0.7686 1.0005 1.0937
FFA(24:1) 1.1659 0.8179 0.9281 1.0656
FFA(24:2) 1.0398 0.9566 0.9567 1.0365
FFA(24:3) 0.5754 0.6028 1.3832 1.1043
lysoPE 16:0; [M-H]-@1.72 1.3031 0.9317 0.9214 0.9455
lysoPE 18:0; [M-H]-@2.48 1.1445 0.9444 0.8570 1.0699
lysoPE 18:1; [M-H]-@1.83 1.1494 0.7790 0.9257 1.0953
lysoPE 18:2; [M-H]-@1.41 1.2174 0.7359 0.9560 1.0585
lysoPE 20:2; [M-H]-@2.09 1.1977 0.9239 1.1449 0.8233
lysoPE 20:3; [M-H]-@1.63 1.4417 0.7420 0.7337 1.1212
lysoPE 20:4; [M-H]-@1.39 1.2484 0.7137 0.8872 1.1091
lysoPE 22:4; [M-H]-@1.93 0.8340 1.1071 0.9098 1.1016
lysoPE 22:5; [M-H]-@1.53 1.4510 0.6140 0.8725 1.0696
N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.45 1.1729 0.9694 1.0769 0.8673
N-(docosanoyl)-sphing-4-enine; [M-H]-@8.46 1.0069 0.8415 0.8991 1.1566
N-(dodecanoyl)-sphing-4-enine; [M-H]-@5.51 0.9884 0.8862 1.0447 1.0269
N-(eicosanoyl)-sphing-4-enine; [M-H]-@7.96 0.6967 0.7451 1.0482 1.2406
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.85 1.0624 0.8692 1.0016 1.0329
N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.44 1.2805 0.7833 1.0237 0.9492
N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.94 1.1421 0.9106 0.9529 1.0114
PA 34:1; [M-H]-@6.87 0.9786 0.9190 1.0222 1.0335
PA 34:2; [M-H]-@6.46 0.9255 0.9378 1.0270 1.0467
PA 34:3; [M-H]-@6.04 1.0429 0.8324 1.1255 0.9620
PA 35:1; [M-H]-@6.95 1.0743 1.0727 0.9919 0.9329
PA 36:1; [M-H]-@7.52 1.0538 0.9703 0.9914 0.9948
PA 36:2; [M-H]-@6.89 1.0090 0.9107 1.0412 1.0072
PA 36:3; [M-H]-@6.50 1.0106 0.8645 1.0205 1.0461
PA 36:4; [M-H]-@6.29 1.1933 1.1033 0.8837 0.9448
PA 36:5; [M-H]-@5.99 1.0535 0.8811 1.0633 0.9820
PA 38:4; [M-H]-@7.02 0.6342 0.9821 1.0026 1.1897
PA 38:5; [M-H]-@6.51 1.1017 0.8858 0.9805 1.0218
PA 38:6; [M-H]-@6.27 1.0689 0.9272 0.8870 1.0924
PA 40:6; [M-H]-@6.51 1.0770 0.9733 0.9544 1.0113
PC 30:1; [M-Ac-H]-@5.60 0.9344 0.8203 0.9720 1.1451
PC 32:0; [M-Ac-H]-@6.83 1.0374 0.9135 1.0305 1.0001
PC 32:1; [M-Ac-H]-@6.36 1.0725 0.8225 0.8928 1.1383
PC 32:2; [M-Ac-H]-@5.80 0.8446 0.8820 1.4211 0.7999
PC 33:2; [M-Ac-H]-@6.15 0.9345 0.6681 1.1530 1.0763
PC 34:1; [M-Ac-H]-@6.88 0.9510 0.9772 0.9855 1.0475
PC 34:2; [M-Ac-H]-@6.42 0.9573 0.9164 1.0082 1.0566
PC 34:3; [M-Ac-H]-@6.00 1.0552 0.8622 1.0938 0.9663
PC 34:4; [M-Ac-H]-@5.75 1.1385 0.6783 0.9749 1.1117
PC 35:0; [M-Ac-H]-@7.73 1.1024 0.8986 1.0270 0.9779
PC 35:1; [M-Ac-H]-@7.23 1.0422 1.0078 0.9372 1.0252
PC 35:2; [M-Ac-H]-@6.74 1.0783 0.8806 1.0020 1.0190
PC 36:1; [M-Ac-H]-@7.55 1.0487 0.9089 0.9908 1.0285
PC 36:2; [M-Ac-H]-@7.02 1.0603 0.8772 1.0153 1.0190
PC 36:3; [M-Ac-H]-@6.60 1.0552 0.8468 1.0472 1.0112
PC 36:4; [M-Ac-H]-@6.30 1.0151 0.8898 1.0180 1.0332
PC 36:5; [M-Ac-H]-@5.93 1.0088 0.8980 0.9429 1.0923
PC 37:1; [M-Ac-H]-@7.83 1.2839 0.8166 1.0862 0.8808
PC 37:2; [M-Ac-H]-@7.37 1.3275 0.8346 1.0635 0.8681
PC 37:4; [M-Ac-H]-@6.68 1.1767 0.8038 0.8985 1.0910
PC 38:0; [M-Ac-H]-@8.18 0.8362 1.2308 0.9939 0.9714
PC 38:1; [M-Ac-H]-@7.67 1.0883 0.9310 1.0385 0.9595
PC 38:2; [M-Ac-H]-@7.73 0.9331 0.8804 0.8844 1.1857
PC 38:3; [M-Ac-H]-@7.35 1.2691 0.6811 1.1010 0.9441
PC 38:4; [M-Ac-H]-@6.96 1.0928 0.9110 0.9654 1.0258
PC 38:5; [M-Ac-H]-@6.56 1.0343 0.9158 0.9758 1.0443
PC 38:6; [M-Ac-H]-@6.21 1.1145 0.9220 0.9546 1.0180
PC 38:7; [M-Ac-H]-@5.60 1.1324 0.9241 0.9791 0.9885
PC 39:5; [M-Ac-H]-@6.72 1.1915 0.8473 1.0332 0.9540
PC 40:5; [M-Ac-H]-@7.02 1.0888 0.9056 0.9960 1.0060
PC 40:6; [M-Ac-H]-@6.82 1.0899 0.9653 0.9332 1.0259
PC 40:7; [M-Ac-H]-@6.37 1.2431 1.0934 1.0477 0.7936
PC 41:6; [M-Ac-H]-@7.09 1.0283 1.0704 1.0552 0.9065
PE 32:0; [M-H]-@6.80 1.2245 1.1940 0.9158 0.8581
PE 32:1; [M-H]-@6.27 1.1721 0.5415 1.3042 0.8999
PE 33:1; [M-H]-@6.63 1.1262 0.9652 1.0052 0.9501
PE 34:1; [M-H]-@6.90 0.8388 0.9554 1.0091 1.0956
PE 34:2; [M-H]-@6.49 1.1333 0.9284 0.9870 0.9796
PE 34:3; [M-H]-@6.06 1.1190 0.8614 1.1012 0.9289
PE 35:0; [M-H]-@7.66 1.2857 0.8219 0.9780 0.9638
PE 35:1; [M-H]-@6.61 1.3608 0.9150 1.0345 0.8345
PE 35:2; [M-H]-@6.73 1.0139 0.8495 1.0364 1.0391
PE 35:4; [M-H]-@6.11 0.9423 0.7185 1.1036 1.0868
PE 36:0; [M-H]-@7.93 1.0082 0.9036 1.0295 1.0205
PE 36:1; [M-H]-@7.51 1.0882 0.8339 1.0971 0.9613
PE 36:3; [M-H]-@6.60 1.1216 0.8528 1.0814 0.9477
PE 36:4; [M-H]-@6.39 0.9133 0.8050 1.0486 1.1020
PE 36:5; [M-H]-@5.96 1.0526 0.7677 0.9646 1.1181
PE 37:4; [M-H]-@6.71 1.0096 0.9384 0.8347 1.1582
PE 38:1; [M-H]-@7.53 1.1986 0.8635 1.0485 0.9302
PE 38:3; [M-H]-@6.70 1.2960 0.7890 1.1072 0.8718
PE 38:4; [M-H]-@7.05 0.9349 0.9396 0.9311 1.1179
PE 38:5; [M-H]-@6.59 1.1407 0.8408 1.0521 0.9675
PE 38:6; [M-H]-@6.18 0.9635 0.9384 1.0162 1.0361
PE 40:2; [M-H]-@7.53 1.1390 1.0073 0.9340 0.9796
PE 40:5; [M-H]-@7.12 1.1558 0.9814 0.9079 1.0051
PE 40:6; [M-H]-@6.95 0.9022 0.9475 0.9095 1.1475
PE 40:7; [M-H]-@6.47 1.1044 1.0137 0.9058 1.0163
PE 40:8; [M-H]-@5.98 1.3890 0.8596 0.9565 0.9105
PG 33:0; [M-H]-@6.07 1.0453 1.1521 0.9409 0.9486
PG 34:2; [M-H]-@5.34 1.1185 0.5985 0.8856 1.2330
PG 35:0; [M-H]-@6.61 0.7658 1.1499 1.1455 0.9257
PG 36:0; [M-H]-@6.89 0.9151 0.9722 1.0294 1.0328
PG 36:2; [M-H]-@6.09 0.9549 0.7793 1.0464 1.0958
PG 36:4; [M-H]-@5.43 1.1511 0.7138 1.1024 0.9856
PG 38:4; [M-H]-@6.06 1.2474 1.2576 0.7211 0.9706
PI 34:1; [M-H]-@5.70 0.9381 0.9288 0.9637 1.0956
PI 34:2; [M-H]-@5.27 1.0017 0.7980 0.9974 1.1022
PI 35:1; [M-H]-@5.91 1.1174 0.8086 1.0698 0.9811
PI 36:1; [M-H]-@6.24 0.9992 0.8887 0.9345 1.1084
PI 36:2; [M-H]-@5.89 0.9829 0.9570 0.9582 1.0635
PI 36:3; [M-H]-@5.39 0.8827 0.8218 1.0397 1.1160
PI 36:4; [M-H]-@5.24 0.8581 0.9253 1.0808 1.0437
PI 38:3; [M-H]-@6.09 1.1405 0.9298 1.0198 0.9490
PI 38:4; [M-H]-@5.90 0.9761 1.0108 0.9256 1.0661
PI 38:5; [M-H]-@5.40 1.0536 0.8172 0.9669 1.0911
PI 40:4; [M-H]-@6.31 1.9928 1.0408 0.7999 0.6432
PI 40:5; [M-H]-@5.95 1.0179 0.9932 0.9072 1.0687
PI 40:6; [M-H]-@5.80 1.0448 1.2211 1.0381 0.8366
plasmenyl-PE 32:0; [M-H]-@7.15 1.0292 0.7126 1.0330 1.1027
plasmenyl-PE 32:1; [M-H]-@6.64 1.1184 0.7802 0.9151 1.1186
plasmenyl-PE 34:0; [M-H]-@7.22 0.8926 0.8931 1.0944 1.0316
plasmenyl-PE 34:1; [M-H]-@7.24 0.8937 0.8655 0.9920 1.1268
plasmenyl-PE 34:2; [M-H]-@6.79 1.0092 0.7640 1.0670 1.0598
plasmenyl-PE 34:3; [M-H]-@6.54 0.7627 0.7473 0.9679 1.2707
plasmenyl-PE 36:0; [M-H]-@7.32 0.9340 0.8297 1.0389 1.0870
plasmenyl-PE 36:1; [M-H]-@7.76 0.9173 0.6922 1.1051 1.1112
plasmenyl-PE 36:4; [M-H]-@6.71 1.1565 0.7097 1.0711 1.0100
plasmenyl-PE 36:5; [M-H]-@6.37 1.3316 0.8294 0.9838 0.9324
plasmenyl-PE 38:1; [M-H]-@8.28 0.9624 1.0652 1.2190 0.8110
plasmenyl-PE 38:2; [M-H]-@7.35 0.9300 0.8091 1.0890 1.0592
plasmenyl-PE 38:3; [M-H]-@7.59 0.9130 1.1919 1.0882 0.8770
plasmenyl-PE 38:4; [M-H]-@6.96 1.2390 0.6638 1.1985 0.8898
plasmenyl-PE 38:5; [M-H]-@6.82 1.0348 0.7658 1.0598 1.0519
plasmenyl-PE 38:6; [M-H]-@6.61 1.2034 0.7188 1.1524 0.9170
plasmenyl-PE 40:4; [M-H]-@7.57 1.0400 0.7404 1.1559 0.9851
plasmenyl-PE 40:5; [M-H]-@7.41 1.0514 0.9602 1.0392 0.9629
plasmenyl-PE 40:6; [M-H]-@7.25 1.3471 0.9658 0.8806 0.9390
plasmenyl-PE 42:5; [M-H]-@7.94 0.9182 0.8536 0.8372 1.2444
plasmenyl-PE 42:6; [M-H]-@7.82 1.1454 1.0728 0.6807 1.1463
Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study

Factors:

F1BPA_DOSE:Control
F2BPA_DOSE:High
F3BPA_DOSE:Low
F4BPA_DOSE:Medium
  logo